Doc, re 9902B enrollment:
Enrollment surged immediately after the 9901 results were presented at the ASCO Prostate Symposium in 2/05. It probably spiked a little bit after the JCO publication this past summer, as well.
As far as 9902A goes, the FDA temporarily halted all cancer vaccine trials in 2002, in order to request that the companies provide quality control info regarding the consistency of the manufactured product. When the FDA lifted the hold later that year, DNDN enrolled a handful more patients and then closed 9902A for good, because they saw encouraging subgroup data from 9901.
DNDN has never really given anyone much useful information regarding the pace of 9902B enrollment.
Market Data 
Markets 
AI
